Drugs / MMV-048
MMV-048
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03195387 | Jan → Sep 2018 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Withdrawn | No outcome recorded |
| Phase 1 | NCT02783820 | May → Dec 2016 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02554799 | Sep → Oct 2015 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02281344 | Oct → Dec 2014 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Terminated | No outcome recorded |
| Phase 1 | NCT02230579 | May 2014 → Feb 2015 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02783833 | May 2016 → Jan 2017 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02880241 | Oct 2017 → Jan 2018 | malaria | Medicines for Malaria Venture | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMV-048 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2041980 ↗ |
| Known as | J3.367.891F | ChEMBL registry synonym — accepted as the source's own label CHEMBL2041980 ↗ |
| Known as | MMV390048 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02783833 ↗ |
| Action | Inhibit | “MMV390048 is a novel antimalarial compound that inhibits Plasmodium phosphatidylinositol-4-kinase.” PMID 31932368 ↗ Mar 2020 |
| Modality | Small molecule | “MMV390048 is a novel antimalarial compound” PMID 31932368 ↗ Mar 2020 |
| Route | Oral | “MMV390048 was generally well tolerated when administered as a single oral dose up to 120 mg” PMID 31932368 ↗ Mar 2020 |